All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Nanoweapons Against Tuberculosis

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F20%3A73604540" target="_blank" >RIV/61989592:15310/20:73604540 - isvavai.cz</a>

  • Result on the web

    <a href="https://obd.upol.cz/id_publ/333184426" target="_blank" >https://obd.upol.cz/id_publ/333184426</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/978-3-030-41858-8_21" target="_blank" >10.1007/978-3-030-41858-8_21</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Nanoweapons Against Tuberculosis

  • Original language description

    The emerging resistance of Mycobacterium tuberculosis and other so-called nontuberculous mycobacteria to clinically used drugs, including second- and third-choice drugs, and the development of cross-resistant or multidrug-resistant strains are alarming. An increase in the number of these infections and the occurrence of nontuberculous opportunistic species are caused by the general immunosuppression of patients, and this fact makes these diseases extremely serious. In spite of the mentioned, the discovery and development of new drugs for systemic administration has not been a priority, as it is a relatively long and risky procedure. Thus, the preparation of nanoparticles/nanoformulations of clinically used drugs can be an approach of first choice. In general, nanomaterials represent a noteworthy alternative for treatment and mitigation of infections caused by resistant pathogens, which are unlikely to develop resistance to nanomaterials. In contrast to conventional drugs, nanomaterials exert efficiency through various mechanisms; in addition to the drug activity itself, they show “intrinsic effects,” such as damaging the membrane morphology, disruption of transmembrane energy metabolism and the membrane electron transport chain, generation of reactive oxygen species, etc. In addition, the application of nanoformulations enhances the bioavailability of active substances and enables targeted delivery and controlled release. This contribution provides an exhaustive overview of the investigated nano-based formulations of antimycobacterially effective drugs, such as isoniazid, ethambutol, rifampicin, and bedaquiline. These nanoformulations increase biological potency, as they can ensure fixed-dose drug combinations or nanoencapsulation of drugs with biologically active matrices. In addition, the route of administration can be modified; thus, nano-based drug delivery systems demonstrate significant potential reducing the dosing frequency and shortening the time of treatment. Brief attention is also given to new nanoformulated antituberculosis vaccines. Future prospects of the application of nanotechnology in the treatment of tuberculosis are briefly outlined.

  • Czech name

  • Czech description

Classification

  • Type

    C - Chapter in a specialist book

  • CEP classification

  • OECD FORD branch

    30107 - Medicinal chemistry

Result continuities

  • Project

    <a href="/en/project/LO1305" target="_blank" >LO1305: Development of the center of advanced technologies and materials</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Book/collection name

    Nanoformulations in Human Health

  • ISBN

    978-3-030-41857-1

  • Number of pages of the result

    35

  • Pages from-to

    469-502

  • Number of pages of the book

    548

  • Publisher name

    Springer Nature Switzerland AG

  • Place of publication

    Cham

  • UT code for WoS chapter